Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Clinical trials of typhoid conjugate vaccine (TCV) are ongoing in 4 countries. Early data confirm safety, tolerability, and immunogenicity of typhoid conjugate vaccine, and early efficacy results are promising. These data support World Health Organization recommendations and planned country introductions. Forthcoming trial data will continue to inform programmatic use of typhoid conjugate vaccine.

Original publication

DOI

10.1093/cid/ciaa370

Type

Journal article

Journal

Clin Infect Dis

Publication Date

29/07/2020

Volume

71

Pages

S155 - S159

Keywords

TyVAC, clinical trials, conjugate vaccine, typhoid